Life Sciences

We create and invest in leading companies in therapeutics and medtech. If we can’t find a company solving an important problem, we create one ourselves — just like we did with Innovent, Denali, Beam, and Ultragenyx to name a few.

Life Sciences Portfolio

Spotlights Portfolio List People Impact

Portfolio List

Develops nausea treatments for surgical and cancer patients.
Acquired by Eagle Pharmaceuticals / EURONEXT: ACPH
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Developing Amber-UI neuromodulation therapy using Picostim for urinary incontinence.
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Developed Ontozry™ (cenobamate) to treat epilepsy.
Acquired by Angelini Pharma
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Developing innovative neuromodulation technology to treat large disease populations.
Develops and commercializes novel digital programmable hearing aid solutions for China.
Developing base editing technology for a range of applications.
Develops and commercializes high-quality hyaluronic acid (HA) based products for the Chinese market.
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Employs DragonFold technology for rapid protein/ligand co-folding to develop novel drugs.
Develops and commercializes consumer healthcare and over-the-counter products.
Provides high-end diagnostics for disease stratification and therapy selection.
Acquired by Metropolis Healthcare
Leader in discovery and development of novel drugs in stem cell related diseases.
Specializing in biosimilars and novel biologics for global healthcare markets.
Developing cell and gene therapy manufacturing solutions for life sciences companies.
Focused on affordable, high-quality medicines for patients worldwide.
Leveraging genomics data science to improve drug R&D and for population health.
Hemostatic product manufacturer in China.
Leading the change in cell & gene therapies & personalized immunotherapy.
Harnessing deep learning to accelerate pharmaceutical development.
Developing novel treatments for unmet medical needs.
Develops and produces insulin pumps.
Developing nasal spray products to prevent respiratory viruses.
Manufactures, develops, and commercializes high quality, affordably priced cardiovascular and general surgery medical devices.
Bringing cell-based therapies to heart failure patients.
Manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Developing small molecule inhibitors of the NLRP3 inflammasome.
Develops innovative therapies to address unmet medical needs in various diseases.
Acquired by SciClone
Accelerating the advancement of globally competitive oncology assets for patients.
Developing treatments for rare diseases using bone-marrow gene therapy.
NASDAQ: ORTX
Promotes the development of cervical cancer screening and prevention in China.
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Designing novel therapeutics against previously undruggable targets using experimental and computational biophysics.
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Developing inhaled therapies for severe respiratory infections and lung conditions.
Developing and commercializing therapies for rare diseases in Asia.
Providing quality medical equipment and supporting healthcare professionals and patients.
Developing innovative inhaled therapies for severe respiratory diseases.
Acquired by Centocor Ortho Biotech
Developing gene therapies for retinal diseases causing blindness.
Developing therapies that target aging at the cellular level.
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Advancing TCR bispecific therapies for cancer and autoimmune disorders.
Transforming global drug discovery with advanced AI and physics-based technologies.
Provides diagnostic equipment designed to offer services and support in the field of obstetrics and gynecology and pathology
Acquired by Hologic
Developing a novel therapy to treat presbyopia.
Developing diagnostic and imaging solutions for healthcare providers.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime. A full list of investments made by funds managed by F-Prime is available below.

People

Alex Pasteur, PhD
Alexander Munoz, MD
Amber Cai, PhD
Anastasiya Sybirna, PhD
Bobby Gaspar, MD, PhD
Brian Yordy, PhD
Carlos Bustamante, PhD
Carolyn Haley, MS, CPA
Catherine Stehman-Breen
Chong Xu, PhD
Clare Bernard
Connie Li
Garth Rapeport
Harlan Krumholz, MD
Jessica Alston, PhD
John Shiver, PhD
Ketan Patel, MD
Kevin Chu
Martin Taylor, PhD
Mike Feng
Muzammil Mansuri, PhD
Namandjé N. Bumpus, PhD
Natasha Rodgers, MB BChir
Nicholas Haining, BM, BCh
Nihal Sinha, MB BChir
Nikhil Ananth
Raj Basak, PhD
Robert Weisskoff, PhD
Stacie Weninger, PhD
Stephen Knight, MD
Thomas Beck, MD

Impact